Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
- PMID: 15667960
- DOI: 10.1016/j.ijrobp.2004.05.021
Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
Abstract
Purpose: To compare long-term outcome using alternative failure definitions after external beam radiation for localized prostate cancer.
Methods and materials: Data from 4839 patients with stage T1b, T1c, and T2 adenocarcinoma of the prostate who were treated solely with external beam radiation between 1986 and 1995 at nine U.S. institutions were analyzed. Outcome using the following prostate-specific antigen (PSA) failure definitions was compared: (1) three consecutive PSA rises backdated (American Society for Therapeutic Radiology and Oncology [ASTRO]), (2) two PSA rises of at least 0.5 ng/mL each, backdated (0.5 x 2), (3) three consecutive PSA rises with failure recorded at the call date (ASTRO call date), (4) PSA > or =current PSA nadir + 2 ng/mL (Houston + 2), (5) PSA > or =current PSA nadir + 3 ng/mL (Houston + 3), (6) PSA >0.2 ng/mL, or (7) PSA >0.5 ng/mL. For definitions 3-7, the failure date was recorded as the date the criterion was met, without backdating.
Results: PSA disease-free survival (PSA-DFS) varied according to the failure definition used with differences of up to 13% with PSA rise definitions and up to 44% with absolute nadir value surgical-type definitions within the first 5 years post-therapy as compared with the ASTRO definition. PSA-DFS was 66%, 66%, 68%, 72%, 15%, and 25% at 5 years postradiation for definitions 2-7, respectively, vs. 59% for the ASTRO definition. Sensitivity and specificity of definitions 2, 4, and 5 were better than for the ASTRO definition, whereas, for definitions 6 and 7, the sensitivity was at least 90% but the specificity was only 9% and 26%, respectively. This analysis shows that the ASTRO definition does not overestimate outcome, particularly in the first 5 years after therapy, as compared with other definitions appropriate to irradiated patients.
Conclusion: There are notable differences in both short- and long-term outcomes after definitive radiation for prostate cancer depending on the failure definition applied. Failure definitions must be tested objectively for sensitivity and specificity in predicting clinical outcome, and it is only in this manner that reasonable choices can be made. Although traditional surgical-type failure definitions do not seem applicable to patients treated with external beam radiation, further analysis of definitions across multiple therapeutic modalities is necessary to determine whether a universal failure definition might be feasible, at least for research and comparative purposes.
Similar articles
-
Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.J Urol. 2005 Mar;173(3):797-802. doi: 10.1097/01.ju.0000152556.53602.64. J Urol. 2005. PMID: 15711272
-
Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):14-9. doi: 10.1016/j.ijrobp.2004.04.064. Int J Radiat Oncol Biol Phys. 2005. PMID: 15629589
-
Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9. doi: 10.1016/j.ijrobp.2004.05.018. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667961
-
High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1306-16. doi: 10.1016/j.ijrobp.2004.08.014. Int J Radiat Oncol Biol Phys. 2005. PMID: 15817332 Review.
-
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.J Urol. 2007 Feb;177(2):540-5. doi: 10.1016/j.juro.2006.10.097. J Urol. 2007. PMID: 17222629 Review.
Cited by
-
Hormone therapy for radiorecurrent prostate cancer.World J Urol. 2013 Dec;31(6):1333-8. doi: 10.1007/s00345-012-0952-8. Epub 2012 Sep 21. World J Urol. 2013. PMID: 22996761 Review.
-
The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5. Prostate Int. 2019. PMID: 31384605 Free PMC article.
-
Choline PET based dose-painting in prostate cancer--modelling of dose effects.Radiat Oncol. 2010 Mar 18;5:23. doi: 10.1186/1748-717X-5-23. Radiat Oncol. 2010. PMID: 20298546 Free PMC article.
-
The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer.Rev Urol. 2007 Spring;9(2):57-62. Rev Urol. 2007. PMID: 17592538 Free PMC article.
-
[Local recurrence of prostate cancer: hormone therapy].Urologe A. 2006 Oct;45(10):1276, 1278-82. doi: 10.1007/s00120-006-1201-9. Urologe A. 2006. PMID: 16998661 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous